News Our latest news and announcements.


Prestigious Cancer Centers Johns Hopkins and Moffitt Complete Patient Enrollment in Post Approval Study for MarginProbe®, Transforming the Standard of Care for Breast Cancer Patients

Dilon Devices has reached another milestone in their MarginProbe® Post Approval Study (PAS) as Johns Hopkins Hospital and Moffitt Cancer Center complete their patient enrollments for the trial.

Innovative Breast Center Showcases New Strategies in the Fight Against Cancer

As part of their whole-person care strategy, Dr. Wilson’s practice uses a new tool, known as MarginProbe, to ensure that a safe margin of tissue is removed around a cancerous tumor as that tumor is removed during surgery.

2018 Highlights in Developments in Breast Cancer Diagnosis and Treatment

With the year coming to an end we put together an overview of the many developments in breast cancer research and treatment from 2018.

Breast Surgeon Dr. Dudak Reflects on Tremendous Changes in Breast Cancer Treatment in the Past 20 Years

“I think for breast cancer, every few months there’s something new and exciting,” the physician shared. “I think there’s always some new technology, new drugs, or new study that comes out that changes our outlook.”

Breast Surgeon Breaks Barriers with Putting the Patient First

“I realized breast surgery put me in the operating room, which I love to do, but it also allowed me to take care of my patients hands-on and I could follow my patients practically forever,” explained Dr. Karen Karsif.

Celebrating the Life and Legacy of Nancy M. Cappello

The team at Dilon is heartbroken over the passing of Nancy M. Cappello, Ph.D. and would like to extend sincere condolences to her family, especially her husband Joseph Cappello, friends, colleagues, and supporters.

Empowering women affected by breast and ovarian cancer at SHARE: A Second Helping of Life fundraising event

In alignment with their mission to ensure that every woman with a diagnosis of breast cancer has an opportunity to receive the most comprehensive care possible, Dilon recently sponsored SHARE at their annual tasting benefit night, A Second Helping of Life.

Breast Surgeon Explains the Impact of Breast Density on Cancer Detection and the Importance of Genetics

There has been much recent discussion around breast cancer in areas of breast density in relation to detection, and the latest observations in the field of genetics. A veteran breast surgeon, Dr. Erica Giblin, took some time to share her thoughts on the impact of both.

Nationally Accredited Breast Center Shares Latest Developments in the Fight Against Breast Cancer

Tidelands Health Breast Center uses the latest technological developments, such as MarginProbe, to refine and improve their surgical outcomes.

Leading Surgeon Reduces Breast Cancer Re-Excision Procedures by Over 50%, Significantly Beating National Average

Dr. Daniel Barnas shares his thoughts here on how to build and nurture strong patient relationships while ensuring the best physical and cosmetic outcomes throughout the breast cancer treatment journey.

How One Breast Surgeon Takes Certain Cases from a Cancer Diagnosis to a Cure in 7-10 Days

Dr. Alice Police has been a surgeon for 30 years and is a pioneer in her field, having founded her own breast treatment center and currently holding the position of Regional Director of Breast Surgery for Northwell Health in Westchester County, NY.

Breast Cancer and BRCA: Recommendations from a Pioneer in the Field

Dr. Beth Anglin is a breast cancer surgeon with almost 20 years of experience and a unique expertise on the genes responsible for many breast cancer cases: BRCA1 and BRCA2. These are the most common genes involved in hereditary breast and ovarian cancers, and the surgeon recently related that out of the 275-300 breast cancer patients she treats annually, she is currently following 200 that all tested positive for the BRCA gene.

cta-img
Medical Device Manufacturer , Dilon Medical Technologies, Inc
How can we help?

Before you commit to a particular
course of treatment, talk to us.